RecruitingPHASE1, PHASE2NCT06897930

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

Studying Autosomal systemic lupus erythematosus

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AstraZeneca
Intervention: AZD0120(biological)
Enrollment: 150 enrolled
Eligibility: 18-70 years · All sexes
Timeline: 2025 – 2029

Study locations (15)

Research Site, San Francisco, California, United States
Research Site, Stanford, California, United States
Research Site, Tampa, Florida, United States
Research Site, Atlanta, Georgia, United States
Research Site, Bethesda, Maryland, United States
Research Site, Boston, Massachusetts, United States
Research Site, St Louis, Missouri, United States
Research Site, New York, New York, United States
Research Site, Syracuse, New York, United States
Research Site, Chapel Hill, North Carolina, United States
Research Site, Charlotte, North Carolina, United States
Research Site, Richmond, Virginia, United States
Research Site, Seattle, Washington, United States
Research Site, Darlinghurst, Australia
Research Site, Melbourne, Australia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06897930 on ClinicalTrials.gov

Other trials for Autosomal systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

See all trials for Autosomal systemic lupus erythematosus →

← Back to all trials